Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 08:09:32 +0200Thu, 06 Jun 2024 14:45:00 +0200Human medicines European public assessment report (EPAR): Rizmoic, naldemedine, Date of authorisation: 18/02/2019, Revision: 11, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rizmoicHuman medicines European public assessment report (EPAR): Rizmoic, naldemedine, Date of authorisation: 18/02/2019, Revision: 11, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rizmoicThu, 06 Jun 2024 14:45:00 +0200Human medicineRizmoic : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4256-en.pdfRizmoic : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4256-en.pdfThu, 06 Jun 2024 08:00:00 +0200Human medicine